We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
Read MoreHide Full Article
Key Takeaways
ALC posted Q3 core EPS of 91 cents, beating estimates, while $2.72 billion in sales missed consensus.
Vision Care, Consumables and Equipment/Other growth helped offset a 2% decline in Implantables sales.
Alcon narrowed 2026 sales growth guidance to about 6% and core EPS growth to 12-14%.
Alcon Inc. (ALC - Free Report) delivered third-quarter 2026 core earnings per share (EPS) of 91 cents, up 15.2% year over year. The figure beat the Zacks Consensus Estimate by 2.3%. The company reports core results based on non-IFRS measures.
Reported EPS was 54 cents, up 12.5% from the year-ago quarter’s level.
Net sales of $2.72 billion increased 5% year over year but missed the consensus estimate by 0.6%.
Following the announcement, ALC's stock price fell 0.3% during the after-market trading session yesterday.
ALC's Q3 Segmental Revenue Performance
Alcon's Surgical sales totaled $1.48 billion, up 4% year over year on a reported as well as constant-currency basis.
Within Surgical, Implantables net sales declined 2% to $422 million, reflecting competitive pressures in the U.S. intraocular lens (IOL) market. Strong PanOptix Pro performance and international market growth partially offset the decline.
Consumables net sales increased 6% to $789 million, driven by procedural volumes, price increases and Valeda consumables. Equipment/Other sales jumped 11% to $269 million, benefiting from equipment launches, including the Unity platform and Valeda.
Vision Care sales reached $1.24 billion, increasing 6% year over year on both a reported and constant-currency basis. Growth across its product categories supported the segment's performance.
Contact Lenses net sales rose 4% to $737 million, reflecting a favorable premium-product mix and price increases, particularly in the United States. At constant currency, sales increased 5%, while declines in legacy products remained a headwind.
Ocular Health sales climbed 8% to $500 million, primarily driven by Alcon's dry-eye portfolio, including Tryptyr and Systane. However, lower contact lens care sales partially offset the growth.
ALC's Q3 Margin Performance
The cost of net sales declined 3.3% year over year to $1.10 billion. Gross profit increased 11.2% to $1.62 billion, while gross margin expanded 340 basis points (bps) to 59.7%.
Selling, general and administrative expenses rose 7.4% to $929 million, while research and development expenses increased 4.4% to $261 million. Other expenses climbed to $60 million from $21 million a year earlier.
Operating income increased 14.8% to $381 million, while operating margin expanded 120 bps to 14%. The improvement reflected tariff refunds, lower amortization and manufacturing efficiencies, partially offset by contingent consideration adjustments, efficiency-related costs and increased sales and marketing spending.
Core operating income rose 13% to $591 million. Core operating margin expanded 160 bps to 21.8%, benefiting from tariff refunds and manufacturing efficiencies.
Alcon's Financial Position and Cash Flow
Alcon exited September 2026 with cash and cash equivalents of $1.71 billion compared with $1.36 billion at the end of June 2026. Total financial debt was $4.77 billion, while net debt was $2.94 billion.
Net cash flow from operating activities for the first nine months of 2026 reached $1.69 billion compared with $1.61 billion in the year-ago period. Free cash flow increased to $1.35 billion from $1.24 billion.
The company repurchased $210 million worth of shares during the third quarter, with approximately $1 billion remaining under its existing authorization. Year-to-date shareholder returns through dividends and repurchases totaled $748 million.
ALC Tightens 2026 Profitability Outlook
Alcon narrowed its 2026 constant-currency net sales growth outlook to approximately 6% from the previous 5-7% projection. The Zacks Consensus Estimate for 2026 revenues is pegged at $11.09 billion, up 7.5% from the 2025 levels.
Core EPS growth at constant currency is now expected between 12% and 14%, compared with the earlier projection of 12-15%. The consensus mark for the company’s 2026 earnings is pegged at $3.50 per share, indicating 14% growth.
Alcon ended the third quarter of 2026 with mixed results, wherein earnings beat estimates but revenues missed the same. However, both the top and bottom lines improved on a year-over-year basis. Revenue growth was supported by Vision Care strength, equipment launches and improved profitability, partially offset by competitive pressures in Implantables. Additionally, expansion of both the margins looks encouraging.
Meanwhile, Alcon's October acquisition of Neurotech Pharmaceuticals strengthened its retinal disease portfolio through ENCELTO, an FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.
On the flip side, the company’s narrowed 2026 guidance doesn’t bode well.
ALC’s Zacks Rank & Key Picks
Alcon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.
View the Zacks #1 Rank List
Image: Bigstock
ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down
Key Takeaways
Alcon Inc. (ALC - Free Report) delivered third-quarter 2026 core earnings per share (EPS) of 91 cents, up 15.2% year over year. The figure beat the Zacks Consensus Estimate by 2.3%. The company reports core results based on non-IFRS measures.
Reported EPS was 54 cents, up 12.5% from the year-ago quarter’s level.
Net sales of $2.72 billion increased 5% year over year but missed the consensus estimate by 0.6%.
Following the announcement, ALC's stock price fell 0.3% during the after-market trading session yesterday.
ALC's Q3 Segmental Revenue Performance
Alcon's Surgical sales totaled $1.48 billion, up 4% year over year on a reported as well as constant-currency basis.
Within Surgical, Implantables net sales declined 2% to $422 million, reflecting competitive pressures in the U.S. intraocular lens (IOL) market. Strong PanOptix Pro performance and international market growth partially offset the decline.
Consumables net sales increased 6% to $789 million, driven by procedural volumes, price increases and Valeda consumables. Equipment/Other sales jumped 11% to $269 million, benefiting from equipment launches, including the Unity platform and Valeda.
Vision Care sales reached $1.24 billion, increasing 6% year over year on both a reported and constant-currency basis. Growth across its product categories supported the segment's performance.
Contact Lenses net sales rose 4% to $737 million, reflecting a favorable premium-product mix and price increases, particularly in the United States. At constant currency, sales increased 5%, while declines in legacy products remained a headwind.
Ocular Health sales climbed 8% to $500 million, primarily driven by Alcon's dry-eye portfolio, including Tryptyr and Systane. However, lower contact lens care sales partially offset the growth.
ALC's Q3 Margin Performance
The cost of net sales declined 3.3% year over year to $1.10 billion. Gross profit increased 11.2% to $1.62 billion, while gross margin expanded 340 basis points (bps) to 59.7%.
Selling, general and administrative expenses rose 7.4% to $929 million, while research and development expenses increased 4.4% to $261 million. Other expenses climbed to $60 million from $21 million a year earlier.
Operating income increased 14.8% to $381 million, while operating margin expanded 120 bps to 14%. The improvement reflected tariff refunds, lower amortization and manufacturing efficiencies, partially offset by contingent consideration adjustments, efficiency-related costs and increased sales and marketing spending.
Core operating income rose 13% to $591 million. Core operating margin expanded 160 bps to 21.8%, benefiting from tariff refunds and manufacturing efficiencies.
Alcon's Financial Position and Cash Flow
Alcon exited September 2026 with cash and cash equivalents of $1.71 billion compared with $1.36 billion at the end of June 2026. Total financial debt was $4.77 billion, while net debt was $2.94 billion.
Net cash flow from operating activities for the first nine months of 2026 reached $1.69 billion compared with $1.61 billion in the year-ago period. Free cash flow increased to $1.35 billion from $1.24 billion.
The company repurchased $210 million worth of shares during the third quarter, with approximately $1 billion remaining under its existing authorization. Year-to-date shareholder returns through dividends and repurchases totaled $748 million.
ALC Tightens 2026 Profitability Outlook
Alcon narrowed its 2026 constant-currency net sales growth outlook to approximately 6% from the previous 5-7% projection. The Zacks Consensus Estimate for 2026 revenues is pegged at $11.09 billion, up 7.5% from the 2025 levels.
Core EPS growth at constant currency is now expected between 12% and 14%, compared with the earlier projection of 12-15%. The consensus mark for the company’s 2026 earnings is pegged at $3.50 per share, indicating 14% growth.
Alcon Price, Consensus and EPS Surprise
Alcon price-consensus-eps-surprise-chart | Alcon Quote
Our Take on Alcon’s Q3 Results
Alcon ended the third quarter of 2026 with mixed results, wherein earnings beat estimates but revenues missed the same. However, both the top and bottom lines improved on a year-over-year basis. Revenue growth was supported by Vision Care strength, equipment launches and improved profitability, partially offset by competitive pressures in Implantables. Additionally, expansion of both the margins looks encouraging.
Meanwhile, Alcon's October acquisition of Neurotech Pharmaceuticals strengthened its retinal disease portfolio through ENCELTO, an FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.
On the flip side, the company’s narrowed 2026 guidance doesn’t bode well.
ALC’s Zacks Rank & Key Picks
Alcon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Medpace (MEDP - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2026 adjusted EPS of $3.00, exceeding the Zacks Consensus Estimate by 14.94%. Revenues of $3.05 billion topped the Zacks Consensus Estimate by 5.84%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 2.5% against the industry’s negative 2.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 15.12%.
Medpace, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $4.84, which surpassed the Zacks Consensus Estimate by 8.76%. Revenues of $716 million beat the Zacks Consensus Estimate by 1.02%.
MEDP has an estimated long-term earnings growth rate of 14.3% compared with the industry’s 13.2%. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 9.77%.
GE HealthCare, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $1.34, which topped the Zacks Consensus Estimate by 10.74%. Revenues of $5.51 billion beat the Zacks Consensus Estimate by 2.87%.
GEHC has an earnings yield of 6.5% compared with the industry’s 2.8%. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.15%.